Heinz Wiendl

List of Publications by Year
in descending order

450 papers	21,555 citations	7568 77 h-index	19749 117 g-index
462 all docs	462 docs citations	462 times ranked	23167 citing authors

#	Article	IF	Citations
1	ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 96-120.	3.0	458
2	Ofatumumab versus Teriflunomide in Multiple Sclerosis. New England Journal of Medicine, 2020, 383, 546-557.	27.0	358
3	Destruction of neurons by cytotoxic T cells: A new pathogenic mechanism in rasmussen's encephalitis. Annals of Neurology, 2002, 51, 311-318.	5.3	353
4	Early detrimental T-cell effects in experimental cerebral ischemia are neither related to adaptive immunity nor thrombus formation. Blood, 2010, 115, 3835-3842.	1.4	315
5	Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Research, 2003, 63, 7462-7.	0.9	312
6	A Functional Role of HLA-G Expression in Human Gliomas: An Alternative Strategy of Immune Escape. Journal of Immunology, 2002, 168, 4772-4780.	0.8	310
7	Regulatory T cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature. Blood, 2013, 121, 679-691.	1.4	300
8	Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responsesin vitro. International Journal of Cancer, 2006, 119, 317-327.	5.1	276
9	Teriflunomide and Its Mechanism of Action in Multiple Sclerosis. Drugs, 2014, 74, 659-674.	10.9	274
10	Clinical Relevance of Brain Volume Measures in Multiple Sclerosis. CNS Drugs, 2014, 28, 147-156.	5.9	254
11	Interferon-Î² enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. Journal of Neuroimmunology, 2004, 155, 172-182.	2.3	249
12	Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. New England Journal of Medicine, 2015, 373, 1418-1428.	27.0	245
13	Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis. Nature Communications, 2020, 11, 247.	12.8	242
14	A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Annals of Neurology, 2005, 58, 50-57.	5.3	203
15	The role of regulatory T cells in multiple sclerosis. Nature Clinical Practice Neurology, 2008, 4, 384-398.	2.5	189
16	Dendritic Cells Ameliorate Autoimmunity in the CNS by Controlling the Homeostasis of PD-1 Receptor+ Regulatory T Cells. Immunity, 2012, 37, 264-275.	14.3	184
17	Diagnostic criteria for Susac syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1287-1295.	1.9	184
18	Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. Journal of Neurology, 2016, 263, 1473-1494.	3.6	179

#	Article	IF	Citations
19	Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends in Immunology, 2005, 26, 373-380.	6.8	175
20	Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity. Brain, 2005, 128, 2689-2704.	7.6	170
21	Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Research and Therapy, 2011, 13, R75.	3.5	170
22	Therapeutic Approaches in Multiple Sclerosis. BioDrugs, 2002, 16, 183-200.	4.6	167
23	Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond. International Journal of Molecular Sciences, 2015, 16, 16414-16439.	4.1	167
24	HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation. Blood, 2007, 110, 568-577.	1.4	162
25	Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E2973-82.	7.1	157
26	Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1190-1197.	1.9	156
27	Microglial Expression of the B7 Family Member B7 Homolog 1 Confers Strong Immune Inhibition: Implications for Immune Responses and Autoimmunity in the CNS. Journal of Neuroscience, 2005, 25, 2537-2546.	3.6	150
28	Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer's disease. Neurobiology of Aging, 2015, 36, 81-89.	3.1	141
29	<scp>l</scp> -Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology, 2013, 81, 865-871.	1.1	140
30	Endothelial TWIK-related potassium channel-1 (TREK1) regulates immune-cell trafficking into the CNS. Nature Medicine, 2013, 19, 1161-1165.	30.7	136
31	Sodium chloride promotes pro-inflammatory macrophage polarization thereby aggravating CNS autoimmunity. Journal of Autoimmunity, 2016, 67, 90-101.	6.5	136
32	VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells. Journal of Experimental Medicine, 2014, 211, 1833-1846.	8.5	134
33	Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation. Science Advances, 2016, 2, e1501678.	10.3	133
34	CD8+ T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery. Brain, 2009, 132, 1236-1246.	7.6	131
35	The Coagulation Factors Fibrinogen, Thrombin, and Factor XII in Inflammatory Disordersâ€"A Systematic Review. Frontiers in Immunology, 2018, 9, 1731.	4.8	130
36	CD4⁺T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients. Neuro-Oncology, 2016, 18, 807-818.	1.2	129

#	Article	IF	Citations
37	How patients with multiple sclerosis acquire disability. Brain, 2022, 145, 3147-3161.	7.6	126
38	Endothelial Basement Membrane Laminin 511 Contributes to Endothelial Junctional Tightness and Thereby Inhibits Leukocyte Transmigration. Cell Reports, 2017, 18, 1256-1269.	6.4	125
39	Neurological Manifestations of COVID-19 Feature T Cell Exhaustion and Dedifferentiated Monocytes in Cerebrospinal Fluid. Immunity, 2021, 54, 164-175.e6.	14.3	119
40	Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e183.	6.0	117
41	Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. Cell, 2018, 175, 1679-1687.e7.	28.9	115
42	Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. Brain, 2003, 126, 1026-1035.	7.6	112
43	Myelin Oligodendrocyte Glycoprotein (MOG₃₅₋₅₅) Induced Experimental Autoimmune Encephalomyelitis (EAE) in C57BL/6 Mice. Journal of Visualized Experiments, 2014, , .	0.3	110
44	Switching from natalizumab to fingolimod. Neurology, 2015, 85, 29-39.	1.1	110
45	Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. Journal of the Neurological Sciences, 2020, 412, 116803.	0.6	110
46	Immune Cells Contribute to Myelin Degeneration and Axonopathic Changes in Mice Overexpressing Proteolipid Protein in Oligodendrocytes. Journal of Neuroscience, 2006, 26, 8206-8216.	3.6	109
47	Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells. Nature Communications, 2016, 7, 11626.	12.8	105
48	Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy. Acta Neuropathologica, 2012, 123, 235-245.	7.7	104
49	Single-cell profiling of CNS border compartment leukocytes reveals that B cells and their progenitors reside in non-diseased meninges. Nature Neuroscience, 2021, 24, 1225-1234.	14.8	103
50	Natalizumab-associated PML. Neurology, 2017, 88, 1197-1205.	1.1	102
51	<scp>NMDAR</scp> encephalitis: passive transfer from man to mouse by a recombinant antibody. Annals of Clinical and Translational Neurology, 2017, 4, 768-783.	3.7	101
52	Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity. Annals of Neurology, 2014, 75, 739-758.	5.3	100
53	CD8+ T-cell pathogenicity in Rasmussen encephalitis elucidated by large-scale T-cell receptor sequencing. Nature Communications, 2016, 7, 11153.	12.8	98
54	Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 660-668.	1.9	97

#	Article	IF	Citations
55	Stromal Interaction Molecules 1 and 2 Are Key Regulators of Autoreactive T Cell Activation in Murine Autoimmune Central Nervous System Inflammation. Journal of Immunology, 2010, 184, 1536-1542.	0.8	96
56	Human muscle cells express a B7â€related molecule, B7â€H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies. FASEB Journal, 2003, 17, 1-16.	0.5	95
57	Imaging matrix metalloproteinase activity in multiple sclerosis as a specific marker of leukocyte penetration of the blood-brain barrier. Science Translational Medicine, 2016, 8, 364ra152.	12.4	94
58	Nur77 serves as a molecular brake of the metabolic switch during T cell activation to restrict autoimmunity. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8017-E8026.	7.1	93
59	Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Multiple Sclerosis Journal, 2013, 19, 1533-1538.	3.0	92
60	Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects. Science Translational Medicine, 2019, 11, .	12.4	92
61	Immune Cell Activation in the Cerebrospinal Fluid of Patients With Parkinson's Disease. Frontiers in Neurology, 2018, 9, 1081.	2.4	91
62	CNS inflammation and neuronal degeneration is aggravated by impaired CD200â€“CD200R-mediated macrophage silencing. Journal of Neuroimmunology, 2008, 194, 62-69.	2.3	89
63	TWIK-related Acid-sensitive K+ Channel 1 (TASK1) and TASK3 Critically Influence T Lymphocyte Effector Functions. Journal of Biological Chemistry, 2008, 283, 14559-14570.	3.4	89
64	Detrimental Contribution of the Immuno-Inhibitor B7-H1 to Rabies Virus Encephalitis. Journal of Immunology, 2008, 180, 7506-7515.	0.8	89
65	Muscle fibers in inflammatory myopathies and cultured myoblasts express the nonclassical major histocompatibility antigen HLA-G. Annals of Neurology, 2000, 48, 679-684.	5.3	88
66	TASK1 modulates inflammation and neurodegeneration in autoimmune inflammation of the central nervous system. Brain, 2009, 132, 2501-2516.	7.6	88
67	Neurons as targets for T cells in the nervous system. Trends in Neurosciences, 2013, 36, 315-324.	8.6	88
68	Regulatory Functions of Natural Killer Cells in Multiple Sclerosis. Frontiers in Immunology, 2016, 7, 606.	4.8	88
69	Computed tomographyâ€“based quantification of lesion water uptake identifies patients within 4.5 hours of stroke onset: A multicenter observational study. Annals of Neurology, 2016, 80, 924-934.	5.3	88
70	Programmed Cell Death-1 Deficiency Exacerbates T Cell Activation and Atherogenesis despite Expansion of Regulatory T Cells in Atherosclerosis-Prone Mice. PLoS ONE, 2014, 9, e93280.	2.5	87
71	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimerâ€™s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica, 2019, 138, 237-250.	7.7	87
72	CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome. Nature Communications, 2019, 10, 5779.	12.8	87

#	Article	IF	Citations
73	Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G. OncoImmunology, 2017, 6, e1250050.	4.6	86
74	Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110396.	3.5	86
75	CD8⁺T cells and neuronal damage: direct and collateral mechanisms of cytotoxicity and impaired electrical excitability. FASEB Journal, 2009, 23, 3659-3673.	0.5	85
76	COVID-19-associated risks and effects in myasthenia gravis (CARE-MG). Lancet Neurology, The, 2020, 19, 970-971.	10.2	85
77	Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e289.	6.0	84
78	Optimizing therapy early in multiple sclerosis: An evidence-based view. Multiple Sclerosis and Related Disorders, 2015, 4, 460-469.	2.0	83
79	Distinct cognitive impairments in different disease courses of multiple sclerosisâ€"A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2017, 83, 568-578.	6.1	83
80	Risks and risk management in modern multiple sclerosis immunotherapeutic treatment. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641983657.	3.5	83
81	Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-Î² in vitro and in vivo: rationale for the therapy of multiple sclerosis. Journal of Neuroimmunology, 2005, 159, 155-164.	2.3	82
82	Fingolimod treatment promotes regulatory phenotype and function of B cells. Annals of Clinical and Translational Neurology, 2015, 2, 119-130.	3.7	82
83	Expression of tollâ€like receptors by human muscle cells in vitro and in vivo: TLR3 is highly expressed in inflammatory and HIV myopathies, mediates ILâ€8 release, and upâ€regulation of NKG2Dâ€ligands. FASEB Journal, 2006, 20, 118-120.	0.5	81
84	Immunoadsorption therapy in autoimmune encephalitides. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e207.	6.0	81
85	The non-classical MHC molecule HLA-G protects human muscle cells from immune-mediated lysis: implications for myoblast transplantation and gene therapy. Brain, 2003, 126, 176-185.	7.6	80
86	Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. Multiple Sclerosis Journal, 2018, 24, 963-973.	3.0	79
87	Cytotoxic CD8⁺T Cellâ€"Neuron Interactions: Perforin-Dependent Electrical Silencing Precedes But Is Not Causally Linked to Neuronal Cell Death. Journal of Neuroscience, 2009, 29, 15397-15409.	3.6	78
88	Blocking of Î±4 Integrin Does Not Protect From Acute Ischemic Stroke in Mice. Stroke, 2014, 45, 1799-1806.	2.0	78
89	Blockade of the kinin receptor B1 protects from autoimmune CNS disease by reducing leukocyte trafficking. Journal of Autoimmunity, 2011, 36, 106-114.	6.5	77
90	A Î²-Lactam Antibiotic Dampens Excitotoxic Inflammatory CNS Damage in a Mouse Model of Multiple Sclerosis. PLoS ONE, 2008, 3, e3149.	2.5	76

#	Article	IF	Citations
91	T cell suppression by naturally occurring HLA-G-expressing regulatory CD4+ T cells is IL-10-dependent and reversible. Journal of Leukocyte Biology, 2009, 86, 273-281.	3.3	76
92	Collateral Bystander Damage by Myelin-Directed CD8+ T Cells Causes Axonal Loss. American Journal of Pathology, 2009, 175, 1160-1166.	3.8	75
93	Skeletal muscle cells actively shape (auto)immune responses. Autoimmunity Reviews, 2018, 17, 518-529.	5.8	74
94	Primary angiitis of the central nervous system: diagnosis and treatment. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641878507.	3.5	74
95	B7â€H1 restricts neuroantigenâ€specific T cell responses and confines inflammatory CNS damage: Implications for the lesion pathogenesis of multiple sclerosis. European Journal of Immunology, 2008, 38, 1734-1744.	2.9	72
96	Immune mechanisms of stroke. Current Opinion in Neurology, 2012, 25, 334-340.	3.6	71
97	Modulation of IL-2RÎ± with daclizumab for treatment of multiple sclerosis. Nature Reviews Neurology, 2013, 9, 394-404.	10.1	71
98	Immune reconstitution therapies: concepts for durable remission in multiple sclerosis. Nature Reviews Neurology, 2020, 16, 56-62.	10.1	71
99	The role of dendritic cells in CNS autoimmunity. Journal of Molecular Medicine, 2010, 88, 535-544.	3.9	70
100	Why Most Acute Stroke Studies Are Positive in Animals but Not in Patients: A Systematic Comparison of Preclinical, Early Phase, and Phase 3 Clinical Trials of Neuroprotective Agents. Annals of Neurology, 2020, 87, 40-51.	5.3	69
101	Specific central nervous system recruitment of HLAâ€G⁺ regulatory T cells in multiple sclerosis. Annals of Neurology, 2009, 66, 171-183.	5.3	67
102	From the Background to the Spotlight: TASK Channels in Pathological Conditions. Brain Pathology, 2010, 20, 999-1009.	4.1	67
103	CD28 Superagonist-Mediated Boost of Regulatory T Cells Increases Thrombo-Inflammation and Ischemic Neurodegeneration during the Acute Phase of Experimental Stroke. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 6-10.	4.3	67
104	Clinical implications of serum neurofilament in newly diagnosed MS patients: A longitudinal multicentre cohort study. EBioMedicine, 2020, 56, 102807.	6.1	67
105	Rasmussen encephalitis treated with natalizumab. Neurology, 2013, 81, 395-397.	1.1	66
106	Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e195.	6.0	66
107	Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 681-686.	1.9	66
108	Intracerebral Dendritic Cells Critically Modulate Encephalitogenic versus Regulatory Immune Responses in the CNS. Journal of Neuroscience, 2009, 29, 140-152.	3.6	65

#	Article	IF	Citations
109	Multiple sclerosis therapeutics. Neurology, 2009, 72, 1008-1015.	1.1	65
110	Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	65
111	Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration. BMJ Open, 2019, 9, e030309.	1.9	63
112	Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmunity Reviews, 2009, 9, 82-89.	5.8	62
113	An Imbalance of Two Functionally and Phenotypically Different Subsets of Plasmacytoid Dendritic Cells Characterizes the Dysfunctional Immune Regulation in Multiple Sclerosis. Journal of Immunology, 2010, 184, 5368-5374.	0.8	62
114	Immune mechanisms of new therapeutic strategies in multiple sclerosisâ€”A focus on alemtuzumab. Clinical Immunology, 2012, 142, 25-30.	3.2	62
115	PML risk stratification using anti-JCV antibody index and L-selectin. Multiple Sclerosis Journal, 2016, 22, 1048-1060.	3.0	62
116	Targeting B cells in relapsingâ€“remitting multiple sclerosis: from pathophysiology to optimal clinical management. Therapeutic Advances in Neurological Disorders, 2017, 10, 51-66.	3.5	62
117	The ups and downs of multiple sclerosis therapeutics. Annals of Neurology, 2001, 49, 281-284.	5.3	61
118	TRPM2 Cation Channels Modulate T Cell Effector Functions and Contribute to Autoimmune CNS Inflammation. PLoS ONE, 2012, 7, e47617.	2.5	61
119	Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro. Journal of Neuroimmunology, 2005, 168, 128-137.	2.3	60
120	Upregulation of K_{2P}5.1 potassium channels in multiple sclerosis. Annals of Neurology, 2010, 68, 58-69.	5.3	60
121	Transcriptional Repressor HIC1 Contributes to Suppressive Function of Human Induced Regulatory T Cells. Cell Reports, 2018, 22, 2094-2106.	6.4	60
122	Expression of antigen processing and presenting molecules by Schwann cells in inflammatory neuropathies. Glia, 2010, 58, 80-92.	4.9	59
123	The Contribution of TWIK-Related Acid-Sensitive K+-Containing Channels to the Function of Dorsal Lateral Geniculate Thalamocortical Relay Neurons. Molecular Pharmacology, 2006, 69, 1468-1476.	2.3	58
124	Comparative efficacy of switching to natalizumab in active multiple sclerosis. Annals of Clinical and Translational Neurology, 2015, 2, 373-387.	3.7	57
125	Neurological immunotherapy in the era of COVID-19 â€” looking for consensus in the literature. Nature Reviews Neurology, 2020, 16, 493-505.	10.1	57
126	Immune-refractory cancers and their little helpersâ€”An extended role for immunetolerogenic MHC molecules HLA-G and HLA-E?. Seminars in Cancer Biology, 2007, 17, 459-468.	9.6	56

#	Article	IF	Citations
127	Regulatory T cells exhibit enhanced migratory characteristics, a feature impaired in patients with multiple sclerosis. European Journal of Immunology, 2010, 40, 3581-3590.	2.9	56
128	Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e70.	6.0	56
129	WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism?. Acta Neuropathologica, 2007, 114, 111-119.	7.7	55
130	Early silent microstructural degeneration and atrophy of the thalamocortical network in multiple sclerosis. Human Brain Mapping, 2016, 37, 1866-1879.	3.6	55
131	Immunophenotyping of Cerebrospinal Fluid Cells in Multiple Sclerosis. JAMA Neurology, 2014, 71, 905.	9.0	54
132	Treatment choices and neuropsychological symptoms of a large cohort of early MS. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e446.	6.0	54
133	Reprogramming the immune repertoire with alemtuzumab in MS. Nature Reviews Neurology, 2013, 9, 125-126.	10.1	53
134	Fine-Tuning of Regulatory T Cell Function: The Role of Calcium Signals and Naive Regulatory T Cells for Regulatory T Cell Deficiency in Multiple Sclerosis. Journal of Immunology, 2013, 190, 4965-4970.	0.8	52
135	The neuroprotective impact of the leak potassium channel TASK1 on stroke development in mice. Neurobiology of Disease, 2009, 33, 1-11.	4.4	51
136	FOXP3+ T regulatory cells in idiopathic inflammatory myopathies. Journal of Neuroimmunology, 2010, 225, 137-142.	2.3	51
137	Licensing of myeloid cells promotes central nervous system autoimmunity and is controlled by peroxisome proliferator-activated receptor Î³. Brain, 2012, 135, 1586-1605.	7.6	51
138	Human CD4 ⁺ HLAâ€G ⁺ regulatory T cells are potent suppressors of graftâ€versusâ€host disease <i>in vivo</i>. FASEB Journal, 2014, 28, 3435-3445.	0.5	51
139	Sex bias in MHC I-associated shaping of the adaptive immune system. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 2168-2173.	7.1	51
140	Therapeutic uses of anti-Î±4-integrin (anti-VLA-4) antibodies in multiple sclerosis. International Immunology, 2015, 27, 47-53.	4.0	50
141	Effects of Natalizumab Treatment on Foxp3+ T Regulatory Cells. PLoS ONE, 2008, 3, e3319.	2.5	49
142	Benefitâ€"Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis. Drugs, 2017, 77, 1755-1768.	10.9	49
143	Melanocortin-1 receptor activation is neuroprotective in mouse models of neuroinflammatory disease. Science Translational Medicine, 2016, 8, 362ra146.	12.4	48
144	The role of leukemia-derived B7-H1 (PD-L1) in tumorâ€"T-cell interactions in humans. Experimental Hematology, 2006, 34, 888-894.	0.4	47

#	Article	IF	Citations
145	Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. Journal of Neurology, 2021, 268, 3961-3968.	3.6	47
146	Evidence of a pathogenic role for CD8 ⁺ T cells in anti-GABA _B receptor limbic encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e232.	6.0	46
147	Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension. Neurology, 2021, 96, e610-e618.	1.1	46
148	Antigen processing and presentation in human muscle: cathepsin S is critical for MHC class II expression and upregulated in inflammatory myopathies. Journal of Neuroimmunology, 2003, 138, 132-143.	2.3	44
149	Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurology, The, 2022, 21, 608-619.	10.2	44
150	Paraneoplastic and non-paraneoplastic autoimmunity to neurons in the central nervous system. Journal of Neurology, 2013, 260, 1215-1233.	3.6	43
151	Effects of Blood Transportation on Human Peripheral Mononuclear Cell Yield, Phenotype and Function: Implications for Immune Cell Biobanking. PLoS ONE, 2014, 9, e115920.	2.5	43
152	Guidelines on dermatomyositis â€“ excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology. JDDG - Journal of the German Society of Dermatology, 2016, 14, 321-338.	0.8	43
153	Evidence for early, non-lesional cerebellar damage in patients with multiple sclerosis: DTI measures correlate with disability, atrophy, and disease duration. Multiple Sclerosis Journal, 2016, 22, 73-84.	3.0	43
154	Postpartum-activation of multiple sclerosis is associated with down-regulation of tolerogenic HLA-G. Journal of Neuroimmunology, 2007, 187, 205-211.	2.3	42
155	CD4⁺T Cells Predominate in Cerebrospinal Fluid and Leptomeningeal and Parenchymal Infiltrates in Cerebral Amyloid Î²â€“Related Angiitis. Archives of Neurology, 2012, 69, 773-7.	4.5	42
156	Targeting Different Monocyte/Macrophage Subsets Has No Impact on Outcome in Experimental Stroke. Stroke, 2017, 48, 1061-1069.	2.0	42
157	Pharmacological Treatment of Early Multiple Sclerosis. Drugs, 2008, 68, 73-83.	10.9	41
158	CT versus MR Techniques in the Detection of Cervical Artery Dissection. Journal of Neuroimaging, 2017, 27, 607-612.	2.0	41
159	The Impact of Dysphagia in Myositis: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2020, 9, 2150.	2.4	41
160	Hide-and-seek in the brain: a role for HLA-G mediating immune privilege for glioma cells. Seminars in Cancer Biology, 2003, 13, 343-351.	9.6	40
161	Immunological and clinical consequences of treating a patient with natalizumab. Multiple Sclerosis Journal, 2012, 18, 335-344.	3.0	40
162	Neurocognitive decline in HIV patients is associated with ongoing Tâ€cell activation in the cerebrospinal fluid. Annals of Clinical and Translational Neurology, 2015, 2, 906-919.	3.7	40

#	Article	IF	Citations
163	Plasma kallikrein modulates immune cell trafficking during neuroinflammation via PAR2 and bradykinin release. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 271-276.	7.1	40
164	Kinetics of IL-6 Production Defines T Effector Cell Responsiveness to Regulatory T Cells in Multiple Sclerosis. PLoS ONE, 2013, 8, e77634.	2.5	40
165	Stroke induces disease-specific myeloid cells in the brain parenchyma and pia. Nature Communications, 2022, 13, 945.	12.8	40
166	Accelerated Course of Experimental Autoimmune Encephalomyelitis in PD-1-Deficient Central Nervous System Myelin Mutants. American Journal of Pathology, 2009, 174, 2290-2299.	3.8	39
167	Volume regulation of murine T lymphocytes relies on voltage-dependent and two-pore domain potassium channels. Biochimica Et Biophysica Acta - Biomembranes, 2011, 1808, 2036-2044.	2.6	39
168	Neurochondrin is a neuronal target antigen in autoimmune cerebellar degeneration. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e307.	6.0	39
169	Can cognitive assessment really discriminate early stages of Alzheimerâ€™s and behavioural variant frontotemporal dementia at initial clinical presentation?. Alzheimer's Research and Therapy, 2017, 9, 61.	6.2	39
170	Human CCR5high effector memory cells perform CNS parenchymal immune surveillance via GZMK-mediated transendothelial diapedesis. Brain, 2019, 142, 3411-3427.	7.6	39
171	Ineffective treatment of PML with pembrolizumab. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e627.	6.0	39
172	Liver X receptor activation promotes differentiation of regulatory T cells. PLoS ONE, 2017, 12, e0184985.	2.5	39
173	An Autoreactive Î³Î´ TCR Derived from a Polymyositis Lesion. Journal of Immunology, 2002, 169, 515-521.	0.8	38
174	Increased cortical curvature reflects white matter atrophy in individual patients with early multiple sclerosis. NeuroImage: Clinical, 2014, 6, 475-487.	2.7	38
175	Blockade of MCAM/CD146 impedes CNS infiltration of T cells over the choroid plexus. Journal of Neuroinflammation, 2018, 15, 236.	7.2	38
176	Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	38
177	Mouse Schwann cells activate MHC class I and II restricted T-cell responses, but require external peptide processing for MHC class II presentation. Neurobiology of Disease, 2010, 37, 483-490.	4.4	37
178	The TASK1 channel inhibitor A293 shows efficacy in a mouse model of multiple sclerosis. Experimental Neurology, 2012, 238, 149-155.	4.1	37
179	FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1811-1822.	3.0	37
180	Gutâ€"CNS-Axis as Possibility to Modulate Inflammatory Disease Activityâ€"Implications for Multiple Sclerosis. International Journal of Molecular Sciences, 2017, 18, 1526.	4.1	37

#	Article	IF	Citations
181	The role of CD8 suppressors versus destructors in autoimmune central nervous system inflammation. Human Immunology, 2008, 69, 797-804.	2.4	36
182	Dementia Apraxia Test (DATE): A Brief Tool to Differentiate Behavioral Variant Frontotemporal Dementia from Alzheimerâ€™s Dementia Based on Apraxia Profiles. Journal of Alzheimer's Disease, 2015, 49, 593-605.	2.6	36
183	Cladribine â€" an old newcomer for pulsed immune reconstitution in MS. Nature Reviews Neurology, 2017, 13, 573-574.	10.1	36
184	Immune signatures of prodromal multiple sclerosis in monozygotic twins. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 21546-21556.	7.1	36
185	Prothrombin and factor X are elevated in multiple sclerosis patients. Annals of Neurology, 2016, 80, 946-951.	5.3	35
186	Vitiligo after alemtuzumab treatment. Neurology, 2018, 91, e2233-e2237.	1.1	35
187	TSPO imaging-guided characterization of the immunosuppressive myeloid tumor microenvironment in patients with malignant glioma. Neuro-Oncology, 2020, 22, 1030-1043.	1.2	35
188	Immune Cell Infiltration into the Brain After Ischemic Stroke in Humans Compared to Mice and Rats: a Systematic Review and Meta-Analysis. Translational Stroke Research, 2021, 12, 976-990.	4.2	35
189	Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres. Multiple Sclerosis Journal, 2022, 28, 257-268.	3.0	35
190	Expression of the B7-related molecule ICOSL by human glioma cells in vitro and in vivo. Glia, 2003, 44, 296-301.	4.9	34
191	The two-pore domain potassium channel TASK3 functionally impacts glioma cell death. Journal of Neuro-Oncology, 2008, 87, 263-270.	2.9	34
192	Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	34
193	The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies. Neurobiology of Disease, 2007, 25, 665-674.	4.4	33
194	Comparative efficacy of first-line natalizumab vs IFN-Î² or glatiramer acetate in relapsing MS. Neurology: Clinical Practice, 2016, 6, 102-115.	1.6	33
195	Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies. Expert Opinion on Investigational Drugs, 2003, 12, 689-712.	4.1	32
196	The Genetic Influence of the Nonclassical MHC Molecule HLA-G on Multiple Sclerosis. Human Immunology, 2007, 68, 422-425.	2.4	32
197	Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibodyâ€"Positive Generalized Myasthenia Gravis. Expert Opinion on Investigational Drugs, 2021, 30, 483-493.	4.1	32
198	Modulation of T-effector function by imatinib at the level of cytokine secretion. Experimental Hematology, 2007, 35, 1266-1271.	0.4	31

#	Article	IF	Citations
199	DTI detects water diffusion abnormalities in the thalamus that correlate with an extremity pain episode in a patient with multiple sclerosis. NeuroImage: Clinical, 2013, 2, 258-262.	2.7	31
200	Dendritic cell vaccination in autoimmune disease. Current Opinion in Rheumatology, 2013, 25, 268-274.	4.3	31
201	Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis. Drugs, 2015, 75, 947-977.	10.9	31
202	Identification of Inflammatory Neuronal Injury and Prevention of Neuronal Damage in Multiple Sclerosis. JAMA Neurology, 2013, 70, 1569-74.	9.0	30
203	A human post-mortem brain model for the standardization of multi-centre MRI studies. NeuroImage, 2015, 110, 11-21.	4.2	30
204	Distinct pattern of lesion distribution in multiple sclerosis is associated with different circulating T-helper and helper-like innate lymphoid cell subsets. Multiple Sclerosis Journal, 2017, 23, 1025-1030.	3.0	30
205	Frequency of Regulatory T Cells is Not Affected by Transient B Cell Depletion Using Anti-CD20 Antibodies in Rheumatoid Arthritis. Open Rheumatology Journal, 2009, 2, 81-88.	0.2	30
206	Muscle-derived positive and negative regulators of the immune response. Current Opinion in Rheumatology, 2005, 17, 714-719.	4.3	29
207	Fulfilling the dream: tolerogenic dendritic cells to treat multiple sclerosis. European Journal of Immunology, 2012, 42, 569-572.	2.9	29
208	Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications. Neurotherapeutics, 2016, 13, 4-19.	4.4	29
209	Novel pathomechanisms in inflammatory neuropathies. Journal of Neuroinflammation, 2017, 14, 232.	7.2	29
210	Express and protect yourself: the potential role of HLA-G on muscle cells and in inflammatory myopathies. Human Immunology, 2003, 64, 1050-1056.	2.4	28
211	Oral Disease-Modifying Treatments for Multiple Sclerosis. CNS Drugs, 2007, 21, 483-502.	5.9	28
212	CD4+NKG2D+ T Cells Exhibit Enhanced Migratory and Encephalitogenic Properties in Neuroinflammation. PLoS ONE, 2013, 8, e81455.	2.5	28
213	Phospholipase D1 mediates lymphocyte adhesion and migration in experimental autoimmune encephalomyelitis. European Journal of Immunology, 2014, 44, 2295-2305.	2.9	28
214	Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biological sero-converters. Multiple Sclerosis Journal, 2018, 24, 563-573.	3.0	28
215	Dietary salt promotes ischemic brain injury and is associated with parenchymal migrasome formation. PLoS ONE, 2018, 13, e0209871.	2.5	28
216	Dietary conjugated linoleic acid links reduced intestinal inflammation to amelioration of CNS autoimmunity. Brain, 2021, 144, 1152-1166.	7.6	28

#	Article	IF	Citations
217	The next-generation sphingosine-1 receptor modulator BAF312 (siponimod) improves cortical network functionality in focal autoimmune encephalomyelitis. Neural Regeneration Research, 2019, 14, 1950.	3.0	28
218	Action of treosulfan in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis and human lymphocytes. Journal of Neuroimmunology, 2003, 144, 28-37.	2.3	27
219	Immunomodulatory treatment strategies in multiple sclerosis. Journal of Neurology, 2008, 255, 15-21.	3.6	27
220	Collateral neuronal apoptosis in CNS gray matter during an oligodendrocyteâ€directed CD8⁺ T cell attack. Glia, 2010, 58, 469-480.	4.9	27
221	Ion channels in autoimmune neurodegeneration. FEBS Letters, 2011, 585, 3836-3842.	2.8	27
222	Natalizumab restores evoked potential abnormalities in patients with relapsingâ€"remitting multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 198-203.	3.0	27
223	Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Multiple Sclerosis Journal, 2022, 28, 910-924.	3.0	27
224	Diffusion Abnormality in Baloâ€™s Concentric Sclerosis: Clues for the Pathogenesis. European Neurology, 2005, 53, 42-44.	1.4	26
225	Deficiency of the negative immune regulator B7-H1 enhances inflammation and neuropathic pain after chronic constriction injury of mouse sciatic nerve. Experimental Neurology, 2010, 222, 153-160.	4.1	26
226	Early and Degressive Putamen Atrophy in Multiple Sclerosis. International Journal of Molecular Sciences, 2015, 16, 23195-23209.	4.1	26
227	Treating a GAD65 Antibody-Associated Limbic Encephalitis with Basiliximab: A Case Study. Frontiers in Neurology, 2015, 6, 167.	2.4	26
228	The farnesoid-X-receptor in myeloid cells controls CNS autoimmunity in an IL-10-dependent fashion. Acta Neuropathologica, 2016, 132, 413-431.	7.7	26
229	CD4+HLA-G+ regulatory T cells: Molecular signature and pathophysiological relevance. Human Immunology, 2016, 77, 727-733.	2.4	26
230	Immune Cell Profiling of the Cerebrospinal Fluid Provides Pathogenetic Insights Into Inflammatory Neuropathies. Frontiers in Immunology, 2019, 10, 515.	4.8	26
231	Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e654.	6.0	26
232	Ocrelizumab initiation in patients with MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	26
233	Advances in pathogenic concepts and therapeutic agents in Rasmussenâ€™s encephalitis. Expert Opinion on Investigational Drugs, 2002, 11, 981-989.	4.1	25
234	Expression of K2P5.1 potassium channels on CD4+T lymphocytes correlates with disease activity in rheumatoid arthritis patients. Arthritis Research and Therapy, 2011, 13, R21.	3.5	25

#	Article	IF	Citations
235	Immune Therapy of Multiple Sclerosis - Future Strategies. Current Pharmaceutical Design, 2012, 18, 4489-4497.	1.9	25
236	Interferon-Beta Therapy of Multiple Sclerosis Patients Improves the Responsiveness of T Cells for Immune Suppression by Regulatory T Cells. International Journal of Molecular Sciences, 2015, 16, 16330-16346.	4.1	25
237	Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1521-1532.	3.0	25
238	Gaps Between Aims and Achievements in Therapeutic Modification of Neuronal Damage (â€œNeuroprotectionâ€). Neurotherapeutics, 2015, 12, 449-454.	4.4	25
239	The quality of cortical network function recovery depends on localization and degree of axonal demyelination. Brain, Behavior, and Immunity, 2017, 59, 103-117.	4.1	25
240	Î±4-integrin receptor desaturation and disease activity return after natalizumab cessation. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e388.	6.0	25
241	Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation. Multiple Sclerosis Journal, 2021, 27, 2062-2076.	3.0	25
242	Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation. Brain Communications, 2021, 3, fcab157.	3.3	25
243	The level of B7 homologue 1 expression on brain DC is decisive for CD8 Treg cell recruitment into the CNS during EAE. European Journal of Immunology, 2009, 39, 1536-1543.	2.9	24
244	Therapeutic Approaches to Multiple Sclerosis. BioDrugs, 2010, 24, 317-330.	4.6	24
245	B7-H1 shapes T-cellâ€"mediated brain endothelial cell dysfunction and regional encephalitogenicity in spontaneous CNS autoimmunity. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E6182-E6191.	7.1	24
246	Mechanisms underlying lesion development and lesion distribution in <scp>CNS</scp> autoimmunity. Journal of Neurochemistry, 2018, 146, 122-132.	3.9	24
247	Immune Cell Profiling During Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of Non-T Cell Populations into the Cerebrospinal Fluidâ€"Results from the ToFingo Successor Study. Frontiers in Immunology, 2018, 9, 1560.	4.8	24
248	Can we predict cognitive decline after initial diagnosis of multiple sclerosis? Results from the German National early MS cohort (KKNMS). Journal of Neurology, 2019, 266, 386-397.	3.6	24
249	B7-H1-Deficiency Enhances the Potential of Tolerogenic Dendritic Cells by Activating CD1d-Restricted Type II NKT Cells. PLoS ONE, 2010, 5, e10800.	2.5	24
250	Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	24
251	Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5â€‰years. Multiple Sclerosis Journal, 2022, 28, 1576-1590.	3.0	24
252	Treatment of active secondary progressive multiple sclerosis with treosulfan. Journal of Neurology, 2007, 254, 884-889.	3.6	23

#	Article	IF	Citations
253	Idiopathic Inflammatory Myopathies: Current and Future Therapeutic Options. Neurotherapeutics, 2008, 5, 548-557.	4.4	23
254	Identification of two-pore domain potassium channels as potent modulators of osmotic volume regulation in human T lymphocytes. Biochimica Et Biophysica Acta - Biomembranes, 2013, 1828, 699-707.	2.6	23
255	Time-resolved transcriptome and proteome landscape of human regulatory T cell (Treg) differentiation reveals novel regulators of FOXP3. BMC Biology, 2018, 16, 47.	3.8	23
256	Expert opinion on the use of cladribine tablets in clinical practice. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642093501.	3.5	23
257	Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity. Brain, 2022, 145, 1711-1725.	7.6	23
258	HLA-G in the Nervous System. Human Immunology, 2007, 68, 286-293.	2.4	22
259	The future of multiple sclerosis therapyâ˜†. Pharmacological Research, 2009, 60, 207-211.	7.1	22
260	Therapeutic Approaches to Multiple Sclerosis. BioDrugs, 2010, 24, 249-274.	4.6	22
261	4-Aminopyridine ameliorates mobility but not disease course in an animal model of multiple sclerosis. Experimental Neurology, 2013, 248, 62-71.	4.1	22
262	Apraxia profile differentiates behavioural variant frontotemporal from Alzheimer's dementia in mild disease stages. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 809-815.	1.9	22
263	Implications of dietary salt intake for multiple sclerosis pathogenesis. Multiple Sclerosis Journal, 2016, 22, 133-139.	3.0	22
264	Targeting Voltage-Dependent Calcium Channels with Pregabalin Exerts a Direct Neuroprotective Effect in an Animal Model of Multiple Sclerosis. NeuroSignals, 2018, 26, 77-93.	0.9	22
265	Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1007-1013.	1.9	22
266	Classification of neurological diseases using multi-dimensional CSF analysis. Brain, 2021, 144, 2625-2634.	7.6	22
267	Animal models in idiopathic inflammatory myopathies: How to overcome a translational roadblock?. Autoimmunity Reviews, 2017, 16, 478-494.	5.8	21
268	Dual action by fumaric acid esters synergistically reduces adhesion to human endothelium. Multiple Sclerosis Journal, 2018, 24, 1871-1882.	3.0	21
269	Temporal Pattern of ICAM-I Mediated Regulatory T Cell Recruitment to Sites of Inflammation in Adoptive Transfer Model of Multiple Sclerosis. PLoS ONE, 2010, 5, e15478.	2.5	21
270	Intercellular exchanges of membrane fragments (trogocytosis) between human muscle cells and immune cells: A potential mechanism for the modulation of muscular immune responses. Journal of Neuroimmunology, 2009, 209, 131-138.	2.3	20

#	Article	IF	Citations
271	Active immunization induces toxicity of diphtheria toxin in diphtheria resistant mice â€” Implications for neuroinflammatory models. Journal of Immunological Methods, 2010, 354, 80-84.	1.4	20
272	CON: Regulatory T Cells Are Protective in Ischemic Stroke. Stroke, 2013, 44, e87-8.	2.0	20
273	FoxP3+ Regulatory T Cells Determine Disease Severity in Rodent Models of Inflammatory Neuropathies. PLoS ONE, 2014, 9, e108756.	2.5	20
274	Specific loss of cellular L-selectin on CD4+ T cells is associated with progressive multifocal leukoencephalopathy development during HIV infection. Aids, 2014, 28, 793-795.	2.2	20
275	The potassium channels TASK2 and TREK1 regulate functional differentiation of murine skeletal muscle cells. American Journal of Physiology - Cell Physiology, 2016, 311, C583-C595.	4.6	20
276	Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation. Journal of Neurology, 2019, 266, 165-173.	3.6	20
277	Human muscle cells express the costimulatory molecule B7â€H3, which modulates muscleâ€"immune interactions. Arthritis and Rheumatism, 2008, 58, 3600-3608.	6.7	19
278	Two pore domain potassium channels in cerebral ischemia: a focus on K2P9.1 (TASK3, KCNK9). Experimental & Translational Stroke Medicine, 2010, 2, 14.	3.2	19
279	Neuron-directed autoimmunity in the central nervous system. Current Opinion in Neurology, 2012, 25, 341-348.	3.6	19
280	CD4+ CD25+ FoxP3+ regulatory T cells suppress cytotoxicity of CD8+ effector T cells: implications for their capacity to limit inflammatory central nervous system damage at the parenchymal level. Journal of Neuroinflammation, 2012, 9, 41.	7.2	19
281	Excitotoxic neuronal cell death during an oligodendrocyte-directed CD8+ T cell attack in the CNS gray matter. Journal of Neuroinflammation, 2013, 10, 121.	7.2	19
282	An assay to quantify species-specific anti-JC virus antibody levels in MS patients. Multiple Sclerosis Journal, 2013, 19, 1137-1144.	3.0	19
283	Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015â€"2020. Drugs, 2021, 81, 1031-1063.	10.9	19
284	Eculizumab versus rituximab in generalised myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 548-554.	1.9	19
285	CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy. Neurology, 2016, 87, 2491-2494.	1.1	18
286	Covarying patterns of white matter lesions and cortical atrophy predict progression in early MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	18
287	Cerebrospinal fluid flow cytometry distinguishes psychosis spectrum disorders from differential diagnoses. Molecular Psychiatry, 2021, 26, 7661-7670.	7.9	18
288	14â€3â€3 Proteins regulate K_{2P}5.1 surface expression on T lymphocytes. Traffic, 2017, 18, 29-43.	2.7	17

#	Article	IF	Citations
289	Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. Multiple Sclerosis and Related Disorders, 2018, 24, 11-19.	2.0	17
290	Leukocyte profiles in blood and CSF distinguish neurosarcoidosis from multiple sclerosis. Journal of Neuroimmunology, 2020, 341, 577171.	2.3	17
291	The NKG2D - IL-15 signaling pathway contributes to T-cell mediated pathology in inflammatory myopathies. Oncotarget, 2015, 6, 43230-43243.	1.8	17
292	PD-1 Regulates Neural Damage in Oligodendroglia-Induced Inflammation. PLoS ONE, 2009, 4, e4405.	2.5	16
293	Shared neural correlates of limb apraxia in early stages of Alzheimer's dementia and behavioural variant frontotemporal dementia. Cortex, 2016, 84, 1-14.	2.4	16
294	Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1235-1241.	3.0	16
295	Apraxia profilesâ€"A single cognitive marker to discriminate all variants of frontotemporal lobar degeneration and Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 363-371.	2.4	16
296	Protective potential of dimethyl fumarate in a mouse model of thalamocortical demyelination. Brain Structure and Function, 2018, 223, 3091-3106.	2.3	16
297	Immune cell profiling in the cerebrospinal fluid of patients with primary angiitis of the central nervous system reflects the heterogeneity of the disease. Journal of Neuroimmunology, 2018, 321, 109-116.	2.3	16
298	Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies. Multiple Sclerosis Journal, 2020, 26, 1866-1876.	3.0	16
299	Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642091178.	3.5	16
300	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Multiple Sclerosis Journal, 2022, 28, 1424-1456.	3.0	16
301	The inflamed peripheral nervous system: update on immune therapies. Current Opinion in Neurology, 2006, 19, 433-436.	3.6	15
302	Lack of evidence for a pathogenic role of T-lymphocytes in an animal model for Charcot-Marie-Tooth disease 1A. Neurobiology of Disease, 2010, 38, 78-84.	4.4	15
303	Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome Array. Genetic Epidemiology, 2015, 39, 601-608.	1.3	15
304	Acute cholecystitis during treatment with alemtuzumab in 3 patients with RRMS. Neurology, 2016, 87, 2380-2381.	1.1	15
305	Defining response profiles after alemtuzumab. Neurology, 2018, 90, 309-311.	1.1	15
306	Amygdala enlargement and emotional responses in (autoimmune) temporal lobe epilepsy. Scientific Reports, 2018, 8, 9561.	3.3	15

#	Article	IF	Citations
307	Impairment of frequency-specific responses associated with altered electrical activity patterns in auditory thalamus following focal and general demyelination. Experimental Neurology, 2018, 309, 54-66.	4.1	15
308	Real-world disability improvement in patients with relapsingâ€"remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program. Multiple Sclerosis Journal, 2021, 27, 719-728.	3.0	15
309	Efficacy and safety of ocrelizumab in patients with relapsingâ€remitting multiple sclerosis with suboptimal response to prior diseaseâ€modifying therapies: A primary analysis from the phase 3b CASTING singleâ€arm, openâ€label trial. European Journal of Neurology, 2022, 29, 790-801.	3.3	15
310	Monoclonal antibodies in neuroinflammatory diseases. Expert Opinion on Biological Therapy, 2013, 13, 831-846.	3.1	14
311	Long-term efficacy of alemtuzumab in polymyositis. Rheumatology, 2015, 54, 560-562.	1.9	14
312	Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010â€"2015. Expert Review of Neurotherapeutics, 2016, 16, 689-700.	2.8	14
313	Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis?. Neurology, 2017, 89, 1098-1100.	1.1	14
314	Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study. EBioMedicine, 2019, 46, 381-386.	6.1	14
315	VLA-2 blockade <i>in vivo</i> by vatelizumab induces CD4+FoxP3+ regulatory T cells. International Immunology, 2019, 31, 407-412.	4.0	14
316	Next-Generation Neuroimmunology: New Technologies to Understand Central Nervous System Autoimmunity. Trends in Immunology, 2020, 41, 341-354.	6.8	14
317	Fc-Receptor Targeted Therapies for the Treatment of Myasthenia gravis. International Journal of Molecular Sciences, 2021, 22, 5755.	4.1	14
318	Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunity. Brain, 2021, 144, 3126-3141.	7.6	14
319	K2P18.1 translates T cell receptor signals into thymic regulatory T cell development. Cell Research, 2022, 32, 72-88.	12.0	14
320	The CD28 related molecule ICOS: T cell modulation in the presence and absence of B7.1/2 and regulational expression in multiple sclerosis. Journal of Neuroimmunology, 2003, 140, 177-187.	2.3	13
321	Human myoblasts modulate the function of antigen-presenting cells. Journal of Neuroimmunology, 2008, 200, 62-70.	2.3	13
322	Antigen-Specific Blockade of Lethal CD8 T-Cell Mediated Autoimmunity in a Mouse Model of Multiple Sclerosis. Journal of Immunology, 2009, 182, 6569-6575.	0.8	13
323	The co-inhibitory molecule PD-1 modulates disease severity in a model for an inherited, demyelinating neuropathy. Neurobiology of Disease, 2009, 33, 96-103.	4.4	13
324	Anti-JC-virus antibody prevalence in a German MS cohort. Multiple Sclerosis Journal, 2012, 18, 1054-1055.	3.0	13

#	Article	IF	Citations
325	Cytotoxic CD8+ T cells and CD138+ plasma cells prevail in cerebrospinal fluid in non-paraneoplastic cerebellar ataxia with contactin-associated protein-2 antibodies. Journal of Neuroinflammation, 2012, 9, 160.	7.2	13
326	Thalamic involvement in patients with neurologic impairment due to Shiga toxin 2. Annals of Neurology, 2013, 73, 419-429.	5.3	13
327	B7-H1 Selectively Controls TH17 Differentiation and Central Nervous System Autoimmunity via a Novel Nonâ€“PD-1â€“Mediated Pathway. Journal of Immunology, 2015, 195, 3584-3595.	0.8	13
328	ALAIN01â€"Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential. BMC Neurology, 2016, 16, 34.	1.8	13
329	Cerebrospinal Fluid Concentrations of Neuronal Proteins Are Reduced in Primary Angiitis of the Central Nervous System. Frontiers in Neurology, 2018, 9, 407.	2.4	13
330	Immunophenotyping of cerebrospinal fluid cells by Chipcytometry. Journal of Neuroinflammation, 2018, 15, 160.	7.2	13
331	Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals. Neurology, 2019, 93, 550-554.	1.1	13
332	Comparing Plasma Exchange to Escalated Methyl Prednisolone in Refractory Multiple Sclerosis Relapses. Journal of Clinical Medicine, 2020, 9, 35.	2.4	13
333	Bcl6 controls meningeal Th17â€“B cell interaction in murine neuroinflammation. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	13
334	Altered neuronal expression of TASK1 and TASK3 potassium channels in rodent and human autoimmune CNS inflammation. Neuroscience Letters, 2008, 446, 133-138.	2.1	12
335	The twoâ€pore domain K₂P channel TASK2 drives human NKâ€cell proliferation and cytolytic function. European Journal of Immunology, 2015, 45, 2602-2614.	2.9	12
336	Recovery of thalamic microstructural damage after Shiga toxin 2-associated hemolyticâ€“uremic syndrome. Journal of the Neurological Sciences, 2015, 356, 175-183.	0.6	12
337	Highlights from the 31st ECTRIMS congress â€“ Barcelona 2015. Multiple Sclerosis Journal, 2016, 22, 7-10.	3.0	12
338	Association of smoking but not HLA-DRB1*15:01, <i>APOE</i> or body mass index with brain atrophy in early multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 661-668.	3.0	12
339	Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015â€“2020. BioDrugs, 2020, 34, 587-610.	4.6	12
340	Blood and cerebrospinal fluid immune cell profiles in patients with temporal lobe epilepsy of different etiologies. Epilepsia, 2020, 61, e153-e158.	5.1	12
341	Multiple sclerosis therapy: An update on recently finished trials. Journal of Neurology, 2007, 254, 1473-1490.	3.6	11
342	Iatrogenic immunosuppression with biologics in MS. Neurology, 2009, 73, 1346-1347.	1.1	11

#	Article	IF	Citations
343	Janus head: the dual role of HLA-G in CNS immunity. Cellular and Molecular Life Sciences, 2011, 68, 407-416.	5.4	11
344	Infectious risk stratification in multiple sclerosis patients receiving immunotherapy. Annals of Clinical and Translational Neurology, 2017, 4, 909-914.	3.7	11
345	Does the environment influence multiple sclerosis pathogenesis via UVB light and/or induction of vitamin D?. Journal of Neuroimmunology, 2019, 329, 1-8.	2.3	11
346	Resolving the cognitive clinico-radiological paradox â€“ Microstructural degeneration of fronto-striatal-thalamic loops in early active multiple sclerosis. Cortex, 2019, 121, 239-252.	2.4	11
347	A fatal case of daclizumab-induced liver failure in a patient with MS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e539.	6.0	11
348	The STING-IFN-Î²-Dependent Axis Is Markedly Low in Patients with Relapsing-Remitting Multiple Sclerosis. International Journal of Molecular Sciences, 2020, 21, 9249.	4.1	11
349	Is APOE Îµ4 associated with cognitive performance in early MS?. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e728.	6.0	11
350	Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110195.	3.5	11
351	Next-generation antibody-based therapies in neurology. Brain, 2022, 145, 1229-1241.	7.6	11
352	Glatiramer Acetate Attenuates Pro-Inflammatory T Cell Responses but Does Not Directly Protect Neurons from Inflammatory Cell Death. American Journal of Pathology, 2010, 177, 3051-3060.	3.8	10
353	Rivaroxaban ameliorates disease course in an animal model of multiple sclerosis. Journal of Neuroimmunology, 2017, 313, 125-128.	2.3	10
354	EMR-integrated minimal core dataset for routine health care and multiple research settings: A case study for neuroinflammatory demyelinating diseases. PLoS ONE, 2019, 14, e0223886.	2.5	10
355	Dysphagia in neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody disease as a surrogate of brain involvement?. European Journal of Neurology, 2021, 28, 1765-1770.	3.3	10
356	Characterization of Extracranial Giant Cell Arteritis with Intracranial Involvement and its Rapidly Progressive Subtype. Annals of Neurology, 2021, 90, 118-129.	5.3	10
357	Impact of T cells on neurodegeneration in antiâ€GAD65 limbic encephalitis. Annals of Clinical and Translational Neurology, 2021, 8, 2289-2301.	3.7	10
358	A genome-wide association study in autoimmune neurological syndromes with anti-GAD65 autoantibodies. Brain, 2023, 146, 977-990.	7.6	10
359	Blockade of inhibitory killer cell immunoglobulin-like receptors and IL-2 triggering reverses the functional hypoactivity of tumor-derived NK-cells in glioblastomas. Scientific Reports, 2022, 12, 6769.	3.3	10
360	What Have Failed, Interrupted, and Withdrawn Antibody Therapies in Multiple Sclerosis Taught Us?. Neurotherapeutics, 2022, 19, 785-807.	4.4	10

#	Article	IF	Citations
361	Antigen recognition properties of a VÎ³1.3VÎ´2-T-cell receptor from a rare variant of polymyositis. Journal of Neuroimmunology, 2004, 152, 168-175.	2.3	9
362	CD3-Positive B Cells: A Storage-Dependent Phenomenon. PLoS ONE, 2014, 9, e110138.	2.5	9
363	Specific aspects of modern life for people with multiple sclerosis: considerations for the practitioner. Therapeutic Advances in Neurological Disorders, 2014, 7, 137-149.	3.5	9
364	A novel automated segmentation method for retinal layers in OCT images proves retinal degeneration after optic neuritis. British Journal of Ophthalmology, 2016, 100, 484-490.	3.9	9
365	Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2017, 17, 32-40.	2.0	9
366	MCAM/CD146 Signaling via PLCÎ³1 Leads to Activation of Î²1-Integrins in Memory T-Cells Resulting in Increased Brain Infiltration. Frontiers in Immunology, 2020, 11, 599936.	4.8	9
367	Fundamental mechanistic insights from rare but paradigmatic neuroimmunological diseases. Nature Reviews Neurology, 2021, 17, 433-447.	10.1	9
368	Multiple sclerosis therapy consensus group (MSTCG): answers to the discussion questions. Neurological Research and Practice, 2021, 3, 44.	2.0	9
369	No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity scoreâ€“matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP). Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110424.	3.5	9
370	Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110582.	3.5	9
371	No effect of immunomodulatory therapy in focal epilepsy with positive glutamate receptor type 3â€"antibodies. Seizure: the Journal of the British Epilepsy Association, 2006, 15, 350-354.	2.0	8
372	Fast track to becoming a regulatory T cell: â€œtrogocytosisâ€•of immune-tolerogenic HLA-G. Blood, 2007, 109, 1796-1797.	1.4	8
373	Effects of Glatiramer Acetate in a Spontaneous Model of Autoimmune Neuroinflammation. American Journal of Pathology, 2014, 184, 2056-2065.	3.8	8
374	Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP). PLoS ONE, 2016, 11, e0144834.	2.5	8
375	Primary B Cell Lymphoma of the CNS Mimicking Anti-LGI1 Limbic Encephalitis. Frontiers in Neurology, 2018, 9, 658.	2.4	8
376	Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination. International Journal of Molecular Sciences, 2019, 20, 5985.	4.1	8
377	Predictors, outcome and characteristics of oropharyngeal dysphagia in idiopathic inflammatory myopathy. Muscle and Nerve, 2021, 63, 874-880.	2.2	8
378	NK Cell Patterns in Idiopathic Inflammatory Myopathies with Pulmonary Affection. Cells, 2021, 10, 2551.	4.1	8

#	Article	IF	Citations
379	Diagnostic utility of cerebrospinal fluid (CSF) findings in seizures and epilepsy with and without autoimmune-associated disease. Seizure: the Journal of the British Epilepsy Association, 2021, 91, 233-243.	2.0	8
380	Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine. Drug Design, Development and Therapy, 2010, 4, 117.	4.3	7
381	Nrf2 and beyond: deciphering the mode of action of fumarates in the inflamed central nervous system. Acta Neuropathologica, 2015, 130, 297-298.	7.7	7
382	Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor). BMC Neurology, 2015, 15, 96.	1.8	7
383	CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Neurology, 2016, 87, 958-959.	1.1	7
384	Cortex Parcellation Associated Whole White Matter Parcellation in Individual Subjects. Frontiers in Human Neuroscience, 2017, 11, 352.	2.0	7
385	Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri^{Â®} Observational Program (TOP). Multiple Sclerosis Journal, 2021, 27, 410-419.	3.0	7
386	Determinants of cognition in autoimmune limbic encephalitisâ€"A retrospective cohort study. Hippocampus, 2021, 31, 1092-1103.	1.9	7
387	The trials and errors in MS therapy. International MS Journal, 2008, 15, 79-90.	0.3	7
388	Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 2151-2153.	3.0	7
389	Postpartum disease activity and breastfeeding in multiple sclerosis revisited. Neurology, 2010, 75, 392-393.	1.1	6
390	Neuroinflammation. Current Opinion in Neurology, 2012, 25, 302-305.	3.6	6
391	Relevance of raised cerebrospinal fluid monocyte levels in patients with frontotemporal dementia. Neurobiology of Aging, 2018, 62, 45-52.	3.1	6
392	A Novel PKD1 Mutation Associated With Autosomal Dominant Kidney Disease and Cerebral Cavernous Malformation. Frontiers in Neurology, 2018, 9, 383.	2.4	6
393	Defining mechanisms of neural plasticity after brainstem ischemia in rats. Annals of Neurology, 2018, 83, 1003-1015.	5.3	6
394	Apraxia screening predicts Alzheimer pathology in frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 562-569.	1.9	6
395	Detecting myasthenia gravis as a cause of unclear dysphagia with an endoscopic tensilon test. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110355.	3.5	6
396	Occurrence of status epilepticus in persons with epilepsy is determined by sex, epilepsy classification, and etiology: a single center cohort study. Journal of Neurology, 2021, 268, 4816-4823.	3.6	6

#	Article	IF	Citations
397	Effect of desire for pregnancy on decisions to escalate treatment in multiple sclerosis care: Differences between MS specialists and non-MS specialists. Multiple Sclerosis and Related Disorders, 2022, 57, 103389.	2.0	6
398	Neuropsychological Performance in Autoimmune Limbic Encephalitis: Evidence from an Immunotherapy-NaÃ¯ve Cohort. Archives of Clinical Neuropsychology, 2022, 37, 738-752.	0.5	6
399	An Enigmatic Case of Acute Mercury Poisoning: Clinical, Immunological Findings and Platelet Function. Frontiers in Neurology, 2017, 8, 517.	2.4	5
400	A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, e638.	6.0	5
401	High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients. Multiple Sclerosis Journal, 2021, 27, 1491-1496.	3.0	5
402	Generation of a Model to Predict Differentiation and Migration of Lymphocyte Subsets under Homeostatic and CNS Autoinflammatory Conditions. International Journal of Molecular Sciences, 2020, 21, 2046.	4.1	5
403	Chances and Challenges of Registry-Based Pharmacovigilance in Multiple Sclerosis: Lessons Learnt from theÂImplementation of the Multicenter REGIMS Registry. Drug Safety, 2021, 44, 7-15.	3.2	5
404	The Innate Immune Response Characterizes Posterior Reversible Encephalopathy Syndrome. Journal of Clinical Immunology, 2021, 41, 1229-1240.	3.8	5
405	Expression of Molecules Involved in Fetal-Maternal Tolerance Allows Human Mesenchymal Stem Cells to Engraft at High Levels across Immunologic Barriers. Blood, 2008, 112, 3480-3480.	1.4	5
406	Trafficking of lymphocytes into the CNS. Oncotarget, 2015, 6, 17863-17864.	1.8	5
407	CT Hypoperfusion-Hypodensity Mismatch to Identify Patients With Acute Ischemic Stroke Within 4.5 Hours of Symptom Onset. Neurology, 2021, 97, e2088-e2095.	1.1	5
408	Impact of diseaseâ€modifying therapies on humoral and cellular immuneâ€responses following SARSâ€CoVâ€2 vaccination in MS patients. Clinical and Translational Science, 2022, 15, 1606-1612.	3.1	5
409	Active immunization with proteolipid protein (190-209) induces ascending paralysing experimental autoimmune encephalomyelitis in C3H/HeJ mice. Journal of Immunological Methods, 2011, 367, 27-32.	1.4	4
410	Murine K2P5.1 Deficiency Has No Impact on Autoimmune Neuroinflammation due to Compensatory K2P3.1- and KV1.3-Dependent Mechanisms. International Journal of Molecular Sciences, 2015, 16, 16880-16896.	4.1	4
411	Impaired Autonomic Responses to Emotional Stimuli in Autoimmune Limbic Encephalitis. Frontiers in Neurology, 2015, 6, 250.	2.4	4
412	Treating refractory post-herpetic anti-N-methyl-d-aspartate receptor encephalitis with rituximab. Oxford Medical Case Reports, 2017, 2017, omx034.	0.4	4
413	Discriminative power of intra-retinal layers in early multiple sclerosis using 3D OCT imaging. Journal of Neurology, 2018, 265, 2284-2294.	3.6	4
414	Impact of FcÎ³R variants on the response to alemtuzumab in multiple sclerosis. Annals of Clinical and Translational Neurology, 2019, 6, 2586-2594.	3.7	4

#	Article	IF	Citations
415	Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response. Neurological Research and Practice, 2019, 1, 40.	2.0	4
416	Serial position effects rapidly distinguish Alzheimerâ€™s from frontotemporal dementia. Journal of Neurology, 2020, 267, 975-983.	3.6	4
417	Patients with a relapsing course of steroidâ€responsive encephalopathy associated with autoimmune thyroiditis exhibit persistent intrathecal CD4+ Tâ€cell activation. European Journal of Neurology, 2021, 28, 1284-1291.	3.3	4
418	Teriflunomide treatment is associated with optic nerve recovery in early multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642199737.	3.5	4
419	Long-Term Sonographical Follow-Up of Arterial Stenosis Due to Spontaneous Cervical Artery Dissection. Frontiers in Neurology, 2021, 12, 792321.	2.4	4
420	Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide. Frontiers in Neurology, 2022, 13, 828616.	2.4	4
421	Multiple sclerosis: advances, excitements, disenchantments. Lancet Neurology, The, 2006, 5, 2-3.	10.2	3
422	Comment on â€œFunctional consequences of Kv1.3 ion channel rearrangement into the immunological synapseâ€ Immunology Letters, 2009, 125, 156-157.	2.5	3
423	Transforming multiple sclerosis trials into practical reality. Lancet Neurology, The, 2011, 10, 493-494.	10.2	3
424	The Neuroinflammation Biobank in the Department of Neurology, University Hospital Muenster, Germany. Biopreservation and Biobanking, 2014, 12, 74-75.	1.0	3
425	Reply to Liu et al.: Haplotype matters: CD226 polymorphism as a potential trigger for impaired immune regulation in multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E908-E909.	7.1	3
426	NMO Spectrum Disorders. Neurology International Open, 2017, 01, E36-E47.	0.4	3
427	Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier. Journal of Visualized Experiments, 2017, , .	0.3	3
428	Circulating lymphocyte levels and relationship with infection status in patients with relapsingâ€“remitting multiple sclerosis treated with daclizumab beta. Multiple Sclerosis Journal, 2018, 24, 1725-1736.	3.0	3
429	Onconeural antigen spreading in paraneoplastic neurological disease due to small cell lung cancer. Oxford Medical Case Reports, 2018, 2018, omy034.	0.4	3
430	The metalloproteinaseâ€disintegrin ADAM10 is exclusively expressed by type I muscle fibers. Muscle and Nerve, 2008, 38, 1049-1051.	2.2	2
431	Immunotherapy of multiple sclerosis. Acta Neuropsychiatrica, 2009, 21, 27-34.	2.1	2
432	Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE. Multiple Sclerosis Journal, 2018, 24, 1883-1891.	3.0	2

#	Article	IF	Citations
433	An Assay to Determine Mechanisms of Rapid Autoantibody-Induced Neurotransmitter Receptor Endocytosis and Vesicular Trafficking in Autoimmune Encephalitis. Frontiers in Neurology, 2019, 10, 178.	2.4	2
434	Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies. Neurology and Therapy, 2021, 10, 803-818.	3.2	2
435	Detecting Myositis as a Cause of Unexplained Dysphagia: Proposal of a Diagnostic Algorithm. European Journal of Neurology, 2021, , .	3.3	2
436	Response to Letter Regarding Article, â€œBlocking of Î±4 Integrin Does Not Protect From Acute Ischemic Stroke in Miceâ€: Stroke, 2014, 45, e196.	2.0	1
437	An Ex vivo Model of an Oligodendrocyte-directed T-Cell Attack in Acute Brain Slices. Journal of Visualized Experiments, 2015, , .	0.3	1
438	The Agony of Choice? Preserved Affective Decision Making in Early Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 914.	2.4	1
439	Author response: Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals. Neurology, 2020, 95, 505-505.	1.1	1
440	4-aminopyridine is not just a symptomatic therapy, it has a neuroprotective effect â€“ No. Multiple Sclerosis Journal, 2020, 26, 1311-1312.	3.0	1
441	Therapie der Multiplen Sklerose. , 2016, , 55-93.		1
442	Lessons from the Past and Future Approaches for Immunologic Therapies in Multiple Sclerosis. Blue Books of Neurology, 2010, , 388-426.	0.1	0
443	Leitlinie Dermatomyositis â€“ Auszug aus der interdisziplinÃren S2kâ€Łeitlinie zu Myositissyndromen der deutschen Gesellschaft fÃ¼r Neurologie. JDDG - Journal of the German Society of Dermatology, 2016, 14, e1.	0.8	0
444	085â€…Clinical outcomes were better for relapsing-remitting multiple sclerosis (RRMS) patients who remained on natalizumab compared to those who switched to oral or injectable therapies after 2 years in the tysabri^{Â®} observational program (TOP). Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A34.2-A34.	1.9	0
445	Prominent T-Cell Responses against the Acetylcholine Receptor Îµ Subunit in Myasthenia Gravis. Neurology Research International, 2019, 2019, 1-5.	1.3	0
446	Longer-Term Safety of B-Cell Therapy With Ocrelizumab in Multiple Sclerosis. Neurology, 2021, 97, 10.1212/WNL.0000000000012716.	1.1	0
447	Review of Novel Immunotherapeutic Strategies for MS. , 2007, , 289-338.		0
448	Dichoptic Metacontrast Masking Functions to Infer Transmission Delay in Optic Neuritis. PLoS ONE, 2016, 11, e0163375.	2.5	0
449	Bilaterality of temporal EEG findings in limbic encephalitis compared to other mesiotemporal epilepsies â€“ a retrospective cohort study. Seizure: the Journal of the British Epilepsy Association, 2022, 96, 98-101.	2.0	0
450	023â€… Relapse outcomes with natalizumab Q4W vs switch to Q6W. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A20.3-A21.	1.9	0